Novartis: Macular Edema trials
The registry lists 39 Macular Edema studies with Novartis as lead sponsor. 0 are open to participants now and 25 have results posted.
Phase 1 2Phase 2 4Phase 3 22Phase 4 8No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular EdemaCompletedNCT04058067Phase 3Results posted
- Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular EdemaCompletedNCT03927690Phase 2Results posted
- Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular EdemaCompletedNCT03917472Phase 3Results posted
- Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein OcclusionTerminatedNCT03810313Phase 3Results posted
- Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein OcclusionTerminatedNCT03802630Phase 3Results posted
- A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular EdemaCompletedNCT03481660Phase 3Results posted
- Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular EdemaCompletedNCT03481634Phase 3Results posted
- Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and SafetyCompletedNCT02953938Phase 4Results posted
- Compare Safety/Efficacy of Labeled vs Wait-Extend Regimen of Lucentis in Turkish Patients With VI Due to DMECompletedNCT02262260Phase 3Results posted
- A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) PatientsCompletedNCT02259088Phase 3Results posted
- Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment PhaseTerminatedNCT02032173Phase 3Results posted
- Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)CompletedNCT01976338Phase 3Results posted
- Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)CompletedNCT01976312Phase 3Results posted
- An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.CompletedNCT01908816Phase 3Results posted
- To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular EdemaCompletedNCT01846299Phase 3Results posted
- Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein OcclusionCompletedNCT01599650Phase 3Results posted
- Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVOCompletedNCT01580020Phase 4Results posted
- Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein OcclusionCompletedNCT01535261Phase 3Results posted
- Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO)CompletedNCT01396083Phase 3Results posted
- Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO)CompletedNCT01396057Phase 3Results posted
- Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes MellitusCompletedNCT01171976Phase 3Results posted
- Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME)CompletedNCT01135914Phase 3Results posted
- Safety and Efficacy of Ranibizumab in Diabetic Macular EdemaTerminatedNCT01131585Phase 3Results posted
- Efficacy of Aliskiren in the Treatment of Diabetic Macular EdemaTerminatedNCT00768040Phase 2Results posted
- Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center InvolvementCompletedNCT00284050Phase 2Results posted
- Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema.CompletedNCT05959304Phase 4
- Ranibizumab 0.5 mg for Diabetic Macular Edema With Initial Intensive Treatment in the Real World Clinical Setting in Korea (Rising K)CompletedNCT05815212
- Special Drug Use Observational Study With Beovu Kit for Intravitreal InjectionCompletedNCT05526729
- A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema PatientsCompletedNCT04635800Phase 1
- Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular EdemaCompletedNCT04543331
- 24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME.WithdrawnNCT02878681Phase 4
- A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular EdemaCompletedNCT02867735Phase 1
- Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular EdemaWithdrawnNCT02258009Phase 4
- Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein OcclusionCompletedNCT01377597Phase 3
- A Clinical Study in Current Medical Practice of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular EdemaCompletedNCT01315275Phase 4
- Ranibizumab "Treat and Extend" in Diabetic Macular EdmaCompletedNCT01297569Phase 4
- Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial TreatmentCompletedNCT01257815Phase 4
- Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO)CompletedNCT00942864Phase 3
- Safety, Tolerability, and Efficacy of AEB071 in the Treatment of UveitisCompletedNCT00615693Phase 2